Also helping Zhou are China blood purification-focused company Jafron Biomedical's 2016 IPO and the growth of telemedicine startup WeDoctor, which is reportedly aiming for a 2020 IPO; …

Kui Zhou, Partner of Sequoia China, is an investor mainly focusing on investments in TMT, Healthcare and Industrial Technology. Among the companies he has led, over a dozen have …

2022年2月7日 · 近日，红杉中国合伙人周逵接受了人民日报健康客户端的专访。 红杉中国从2006年起就已入局医疗健康领域，一直到如今覆盖创新药、医疗器械、医疗服务、精准医疗 …

"Kui Zhou is a Partner of Sequoia Capital China. Prior to joining Sequoia Capital in 2005, Kui served as a Senior Vice President at Legend Capital where he was responsible for …

该片用纪实手法创作，以和田的灿烂文化、悠久历史、地理风貌、独特生态、遗址古迹、丝路文明、绿洲文化和独特民俗、社会变迁、时代进步等为主要内容，发挥梳理和保存和田文化记忆， …

‪Associate Professor, Nanchang University 南昌大学‬ - ‪‪Cited by 788‬‬ - ‪3D Bioprinting‬

Mr. Kui Zhou has served as our director since October 2017. He is a partner at Sequoia Capital China who has been focusing on early investments in the technology, media, telecom and …

2001年12月23日 · Director/Board Member at Yunnan Botanee Bio-Technology Group Co., Ltd., Discover Kui Zhou's known position history, network and 100 relationships. Find out about his …

Has led over a dozen companies to list on capital markets at home and abroad, including the stock exchanges in America and Hong Kong, China, and A-share markets in mainland China. …

"Kui Zhou is a Partner of Sequoia Capital China. Prior to joining Sequoia Capital in 2005, Kui served as a Senior Vice President at Legend Capital where he was responsible for …